Arcellx
Arcellx is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible. Arcellx’s lead product candidate, CART-ddBCMA, is being developed for the treatment of relapsed or refractory multiple myeloma (r/r MM) in an ongoing Phase 1 study. CART-ddBCMA has been granted Fast Track, Orphan Drug, and Regenerative Medicine Advanced Therapy designations by the U.S. Food and Drug Administration. Arcellx is also advancing its dosable and controllable CAR-T therapy, ARC-SparX, into the clinic through two programs: ACLX-001 in r/r MM and ACLX-002 in relapsed or refractory acute myeloid leukemia.
Domain
arcellx.com
Country
United StatesIndustry
BiopharmaEmployees
101-250
Last Funding
$200.0M
Founded
2014
Tech Stack (19 technologies)
Frequently Asked Questions
What technologies does Arcellx use?+
Arcellx uses 19 technologies including Contact Form 7, Font Awesome, Google Tag Manager.
What industry is Arcellx in?+
Arcellx operates in the Biopharma industry.
Where is Arcellx based?+
Arcellx is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026